Approval · Notice of Compliance 15559 · 2012
TYSABRI: Notice of Compliance 15559
Issued April 25, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15559
- Date
- April 25, 2012
- Company
- Biogen Idec Canada Inc
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update
- Therapeutic class
- Selective adhesion molecule inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TYSABRI | Not yet assigned | — |
Medicinal ingredients
- NATALIZUMAB 20 MG per ML